Industry Newsroom

Goldman Sachs Invests USD150m in Indian Biopharma Biocon Biologics

Goldman Sachs has agreed to invest INR11.25b (approximately USD150m) in India-based biopharmaceuticals company Biocon Biologics. True North and Tata Capital Growth Fund invested in the company earlier this year. The transaction is subject to approvals. Read more